Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. Issue 2 (January 2014)
- Record Type:
- Journal Article
- Title:
- Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. Issue 2 (January 2014)
- Main Title:
- Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
- Authors:
- Galon, Jérôme
Mlecnik, Bernhard
Bindea, Gabriela
Angell, Helen K
Berger, Anne
Lagorce, Christine
Lugli, Alessandro
Zlobec, Inti
Hartmann, Arndt
Bifulco, Carlo
Nagtegaal, Iris D
Palmqvist, Richard
Masucci, Giuseppe V
Botti, Gerardo
Tatangelo, Fabiana
Delrio, Paolo
Maio, Michele
Laghi, Luigi
Grizzi, Fabio
Asslaber, Martin
D'Arrigo, Corrado
Vidal‐Vanaclocha, Fernando
Zavadova, Eva
Chouchane, Lotfi
Ohashi, Pamela S
Hafezi‐Bakhtiari, Sara
Wouters, Bradly G
Roehrl, Michael
Nguyen, Linh
Kawakami, Yutaka
Hazama, Shoichi
Okuno, Kiyotaka
Ogino, Shuji
Gibbs, Peter
Waring, Paul
Sato, Noriyuki
Torigoe, Toshihiko
Itoh, Kyogo
Patel, Prabhu S
Shukla, Shilin N
Wang, Yili
Kopetz, Scott
Sinicrope, Frank A
Scripcariu, Viorel
Ascierto, Paolo A
Marincola, Francesco M
Fox, Bernard A
Pagès, Franck
… (more) - Abstract:
- <abstract abstract-type="main" id="path4287-abs-0001"> <title>Abstract</title> <p id="path4287-para-0001"> <bold>The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph nodes (N) and evidence for distant metastases (M). However, it is now recognized that the clinical outcome can vary significantly among patients within the same stage. The current classification provides limited prognostic information and does not predict response to therapy. Multiple ways to classify cancer and to distinguish different subtypes of colorectal cancer have been proposed, including morphology, cell origin, molecular pathways, mutation status and gene expression‐based stratification. These parameters rely on tumour‐cell characteristics. Extensive literature has investigated the host immune response against cancer and demonstrated the prognostic impact of the <italic>in situ</italic> immune cell infiltrate in tumours. A methodology named 'Immunoscore' has been defined to quantify the <italic>in situ</italic> immune infiltrate. In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the<abstract abstract-type="main" id="path4287-abs-0001"> <title>Abstract</title> <p id="path4287-para-0001"> <bold>The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph nodes (N) and evidence for distant metastases (M). However, it is now recognized that the clinical outcome can vary significantly among patients within the same stage. The current classification provides limited prognostic information and does not predict response to therapy. Multiple ways to classify cancer and to distinguish different subtypes of colorectal cancer have been proposed, including morphology, cell origin, molecular pathways, mutation status and gene expression‐based stratification. These parameters rely on tumour‐cell characteristics. Extensive literature has investigated the host immune response against cancer and demonstrated the prognostic impact of the <italic>in situ</italic> immune cell infiltrate in tumours. A methodology named 'Immunoscore' has been defined to quantify the <italic>in situ</italic> immune infiltrate. In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC/UICC TNM classification. An international consortium has been initiated to validate and promote the Immunoscore in routine clinical settings. The results of this international consortium may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM‐I (TNM‐Immune). © 2013 The Authors. <italic>Journal of Pathology</italic> published by John Wiley &amp; Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</bold> </p> </abstract> … (more)
- Is Part Of:
- Journal of pathology. Volume 232:Issue 2(2014)
- Journal:
- Journal of pathology
- Issue:
- Volume 232:Issue 2(2014)
- Issue Display:
- Volume 232, Issue 2 (2014)
- Year:
- 2014
- Volume:
- 232
- Issue:
- 2
- Issue Sort Value:
- 2014-0232-0002-0000
- Page Start:
- 199
- Page End:
- 209
- Publication Date:
- 2014-01
- Subjects:
- Pathology -- Periodicals
616.07 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/path.4287 ↗
- Languages:
- English
- ISSNs:
- 0022-3417
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5029.900000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3900.xml